China Tests First Acne Vaccine in Clinical Trials

Imagine a world where stubborn acne could be treated with a vaccine instead of endless antibiotic cycles and harsh creams. That future just took a major step forward in China.

WestVac BioPharma launched clinical trials for the country's first acne vaccine on December 30 at West China Hospital of Sichuan University. The recombinant protein-based treatment trains the immune system to produce antibodies against Cutibacterium acnes, a normally harmless skin bacterium that causes inflammation when it grows out of control.

Unlike preventive vaccines, this therapeutic shot targets existing acne conditions. It's specifically designed for patients who don't respond well to conventional treatments or experience frequent relapses after their skin clears.

The timing couldn't be better. More than 85% of adolescents worldwide experience acne, and research links severe cases to increased risks of anxiety, depression, and even suicidal thoughts. Current treatment options like antibiotics, hormonal drugs, and vitamin A derivatives often come with significant side effects, drug resistance issues, and high relapse rates.

China isn't alone in this race. French pharmaceutical giant Sanofi began clinical trials for an mRNA-based acne vaccine in July 2025. A team of U.S. researchers also published promising results on an enzyme-based vaccine in Nature Communications last December, though that version hasn't reached human trials yet.

The Ripple Effect

This vaccine represents more than just clearer skin. It signals a fundamental shift in how medicine approaches one of the most psychologically damaging skin conditions affecting young people.

For teens and adults who've spent years cycling through ineffective treatments, this immune-based approach offers genuine hope for long-term relief. If successful, the vaccine could reduce the physical scarring and emotional toll that acne takes on millions globally.

Lead researcher Li Jiong emphasized that the clinical trials will carefully evaluate antibody levels, immune response strength, and treatment duration across different patient groups. West China Hospital clarified the vaccine won't be for everyone, focusing instead on those with treatment-resistant or frequently recurring cases.

The world's three competing acne vaccines each take different scientific approaches, increasing the odds that at least one will succeed.